作者: Jonathan C. Dudley , Grzegorz T. Gurda , Li-Hui Tseng , Derek A. Anderson , Guoli Chen
DOI: 10.1007/S40291-014-0091-6
关键词: Human genetics 、 Metastatic melanoma 、 Cancer research 、 Melanoma 、 Quality assurance 、 Pathology 、 Medicine 、 Molecular medicine 、 Mutation 、 Vemurafenib 、 Standard of care
摘要: Background Detection of BRAF mutations is an established standard care to predict small-molecule inhibitor (vemurafenib) response in metastatic melanoma. Molecular assays should be designed detect not only the most common p.V600E mutation, but also p.V600K and other non-p.V600E mutations.